Showing 7401-7410 of 8649 results for "".
- Seoul Semiconductor Proves the Effect of SunLike Lighting on Myopia Improvementhttps://modernod.com/news/seoul-semiconductor-proves-the-effect-of-sunlike-lighting-on-myopia-improvement/2480573/Seoul Semiconductor announced that it has confirmed SunLike lighting’s effect on improving myopia, along with SERI_Singapore Eye Research Institute. In order to prove the correlation between health and SunLike, a natural lighting technology developed through years of R&D,
- Bausch + Lomb Files Registration Statement for Proposed Initial Public Offeringhttps://modernod.com/news/bausch-lomb-corporation-files-registration-statement-and-preliminary-prospectus-for-proposed-initial-public-offering/2480570/Bausch Health Companies announced that in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch + Lomb, has publicly filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (SE
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-36-months-in-phase-2b-study/2480567/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 36-month analysis of the phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. <
- UnitedHealthcare Enhances Eye Care Program by Helping Reduce People’s Exposure to Blue Lighthttps://modernod.com/news/unitedhealthcare-enhances-eye-care-program-by-helping-reduce-peoples-exposure-to-blue-light/2480563/UnitedHealthcare is investing in new ways to help children and adults across the country reduce their exposure to blue light and support their overall eye health amid ongoing use of screens during COVID-19 and the greater reliance on remote school and work. Through multiple initiatives,
- Reichert Technologies Celebrates 100 Years of Phoroptorhttps://modernod.com/news/reichert-technologies-celebrates-100-years-of-phoroptor/2480561/Reichert Technologies is celebrating 100 years of the Phoroptor. On January 10, 1922, the United States Patent & Trademark Office granted a registered trademark to the word "Phoroptor" to coincide with its first model release. Ever since, Phoroptor has been synonymous with vision ca
- Using Cryo-Electron Tomography, UCI Researchers Reveal Molecular Mechanisms Underlying Mutations Within the Eye that Lead to Blindnesshttps://modernod.com/news/using-cryo-electron-tomography-uci-researchers-reveal-molecular-mechanisms-underlying-mutations-within-the-eye-that-lead-to-blindness/2480552/For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed at a molecular level key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrum
- Nicox European Patent Seals Zerviate Major Market Coverage to 2030https://modernod.com/news/nicox-european-patent-seals-zerviate-major-market-coverage-to-2030/2480545/Nicox announced that patent EP2408453, covering the company’s product Zerviate (cetirizine ophthalmic solution) 0.24%, has been issued by the European Patent Office (EPO). The patent covers the formulation of Zerviate which is commercialized in the US by exclusive US licensee
- Omeros Completes Sale of Omidria Franchise to Rayner Surgicalhttps://modernod.com/news/omeros-completes-sale-of-omidria-franchise-to-rayner-surgical/2480536/Omeros announced that it has completed the sale of Omidria (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group. The transaction was completed pursuant to an Asset Purchase Agreement that was
- Sight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD)https://modernod.com/news/sight-sciences-receives-fda-510k-clearance-of-the-tearcare-system-for-treatment-of-meibomian-gland-dysfunction-mgd/2480531/Sight Sciences announced FDA 510(k) clearance of the TearCare System for the treatment of meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED). The indication clears TearCare for the application of localized heat therapy in adult patients with
- CORE Names “Top 10 of 2021” Scientific Papers for Eye Care Communityhttps://modernod.com/news/core-names-top-10-of-2021-scientific-papers-for-eye-care-community/2480525/In a year like no other, the Centre for Ocular Research & Education (CORE) has published a record 66 scientific and clinical educational papers on topics that advance academic and clinical knowledge in optometry and ophthalmology. The organization today announced its “Top 10 o